No risk of pancreatic cancer risk among diabetes patients receiving GLP-1RAs: JAMA
Raised concerns suggest that GLP-1RA (glucagon-like peptide-1 receptor agonists), could potentially increase the risk of developing pancreatic cancer.
An Original Investigation on Pharmacy and Clinical Pharmacology published in JAMA Network Open concluded that In type 2 diabetes patients using GLP-1RA medication, there was no evidence supporting increased pancreatic cancer risk after seven years. However, continued monitoring beyond this period is still necessary.
In this study, adult patients with type 2 diabetes insured by Clalit Healthcare Services in Israel were followed from 2009 to 2017. The exposure was treatment with GLP-1RA compared to basal insulin.
In a Cox model, pancreatic cancer incidence was compared based on weighted cumulative exposure to GLP-1RA and basal insulin, adjusting for confounding variables with a time origin at two years after diabetes diagnosis. Sensitivity analyses were conducted using propensity score-matched and prevalent new-user designs, emphasising results from the fifth to seventh year after medication.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.